Overview

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Status:
Active, not recruiting

Trial end date:
2022-04-29

Target enrollment:

Participant gender:

Summary

This study aims at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- ABC after recurrence or progression on letrozole or anastrozole. The rationale of this study is based on the following: - Proven everolimus activity in breast cancer in combination with exemestane - Efficacy and manageable safety profile of everolimus in combination with exemestane in the Asian subpopulation of BOLERO-2

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Aromatase Inhibitors
Estrogens
Everolimus
Exemestane
Sirolimus